Teva Maintains Innocence After DoJ Price Fixing Charge
Consumers Allegedly Overcharged By $350m
Teva has insisted it “did not participate in price fixing,” after being charged by the US Department of Justice with conspiring to fix prices for generic medicines, resulting in consumers being “allegedly overcharged at least $350m.”
You may also be interested in...
Teva Reaches ‘Modest’ Settlement With Georgia Over Price-Fixing Allegations
Teva has made its third settlement with a US state following the Department of Justice’s price-fixing investigation, agreeing to pay Georgia $3.34m in exchange for the dismissal of all claims against the company and its affiliates.
End Of Schultz Era Looms For Teva
Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.